机译:Sanad II研究Nevetiracetam,Zonisamide或Lamotrigine的新诊断综合症癫痫的有效性和成本效果:开放标签,非劣势,多期,第4期,随机对照试验
Univ Liverpool Dept Mol &
Clin Pharmacol Liverpool L9 7LJ Merseyside England;
Univ Liverpool Dept Hlth Data Sci Liverpool Merseyside England;
Alder Hey Childrens Hlth Pk Roald Dahl EEG Unit Liverpool Merseyside England;
Walton Ctr NHS Fdn Trust Liverpool Merseyside England;
Univ Glasgow Sch Med Glasgow Lanark Scotland;
Univ Liverpool Dept Mol &
Clin Pharmacol Liverpool L9 7LJ Merseyside England;
Univ Liverpool Dept Hlth Data Sci Liverpool Merseyside England;
Bangor Univ Ctr Hlth Econ &
Med Evaluat Bangor Gwynedd Wales;
Bangor Univ Ctr Hlth Econ &
Med Evaluat Bangor Gwynedd Wales;
Univ Liverpool Dept Hlth Data Sci Liverpool Merseyside England;
Univ Liverpool Dept Mol &
Clin Pharmacol Liverpool L9 7LJ Merseyside England;
Univ Liverpool Liverpool Clin Trials Ctr Liverpool Merseyside England;
Univ Liverpool Liverpool Clin Trials Ctr Liverpool Merseyside England;
Addenbrookes Hosp NHS Fdn Trust Cambridge England;
Bolton NHS Fdn Trust Royal Bolton Hosp Bolton Lancs England;
Royal Hallamshire Hosp Dept Neurol Sheffield S Yorkshire England;
Univ Leeds Sch Med Leeds W Yorkshire England;
Salford Royal NHS Fdn Trust Manchester Lancs England;
Univ Hosp Wales Alan Richens Epilepsy Unit Cardiff Wales;
机译:Sanad II研究Levetiracetam,Zonisamide或Lamotrigine进行新诊断局灶性癫痫的有效性和成本效果:开放标签,非劣等,多期,第4期,随机对照试验(Vol 397,PG 1363,2021)
机译:Sanad II研究了缬氨酸戊甲酸的有效性和成本效益,对新诊断的广义和无殖民癫痫发作:开放标签,非劣势,多期,第4期,随机对照试验
机译:Sanad II研究VALPROATE与Levetiracetam对新诊断的广义和无分类癫痫的有效性和成本性:开放标签,非劣势,多期,第4期,随机对照试验(VOL 397,PG 1375,2021)
机译:风险适应的静脉内莫尔甘蔗用佐剂沙利度胺和地塞米松,用于新诊断的未经治疗的全身淀粉样蛋白症患者:II期试验的中期报告
机译:协议:用于务实随机对照试验的研究方案比较Levetiracetam和Zonisamide对癫痫的标准治疗的有效性和成本效果:标准和新的抗癫痫药物(Sanad-II)的比较
机译:Sanad II研究valproate的有效性和成本效益,对新诊断的广义和无殖民癫痫症的veLetiracetam:开放标签,非劣势,多期,第4期,随机对照试验